Pharmstandard has participated in a series B round for the biopharmaceutical company, which focuses on metabolic and orphan diseases.
US-based biopharmaceutical company Allena Pharmaceuticals has raised $25m in a series B round featuring participation from Pharmstandard International, a holding company of Russia-based pharmaceutical company OJSC Pharmstandard.
The round was led by HBM Partners and also included Frazier Healthcare, Third Rock Ventures and Bessemer Venture Partners. Allena previously raised $15m in a 2011 series A round that featured Bessemer, Frazier and Third Rock.
Allena develops therapies for metabolic and orphan diseases, and has recently launched a Phase 2 trial for…
